Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ViaDerm-hPTH (1-34) versus Forteo in postmenopausal women with osteoporosis or osteopenia
2007-004633-41Phase 2Completed
- Sponsor
- TransPharma Medical Ltd.
- Start
- Sep 2007
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ViaDerm hPTH (1-34) and teriparatide in osteoporosis and osteopenia (3 arms), sponsored by TransPharma Medical Ltd. Primary endpoints: Change in procollagen 1 N-terminal Polypeptide (P1NP-1) from baseline to Day 96 and Change in CTX-1 from baseline to Day 96. Started Sep 2007; status: completed.
02
Drugs
ViaDerm hPTH (1-34)teriparatide
03
Conditions
osteoporosisosteopenia
Beyond the preview
Go deeper on 2007-004633-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004633-41.